
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals is a sound investment choice, backed by strong financial performance and promising developments in their pipeline and recent acquisition. However, there are potential risks and challenges to consider, such as reliance on a few key products and the need for ongoing successful partnerships. The company's commitment to sustainability is also noteworthy.
Bears say
Ligand Pharmaceuticals is facing several risks that could negatively impact its stock, including potential declines in royalty revenue, dependence on Captisol sales, potential acquisition integration issues, and risks associated with drugs in development. With several pivotal data readouts and a Phase 4 study underway, there may be volatility in the near future for Travere's FILSPARI, although initial uptake has been strong. Additionally, while Ligand has made strides in diversity with two women on its board and senior management team, there is room for improvement in terms of gender representation.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares